Opportunity Information: Apply for PAR 13 005
Apply for PAR 13 005
- The National Institutes of Health in the environment health income security and social services sector is offering a public funding opportunity titled "Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research 93.867 Vision Research.
- This funding opportunity was created on Oct 3, 2012 and posted on Oct 3, 2012.
- Applicants must submit their applications by Jan 30, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: For profit organizations other than small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments State governments Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments Public housing authorities/Indian housing authorities Independent school districts Native American tribal governments (Federally recognized) County governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21) opportunity, Funding Opportunity Number PAR-13-005, is an NIH grant program designed to kick-start early-stage translational research aimed at developing or improving medical therapeutics that can reduce death and serious illness after acute exposure to high-priority chemical threat agents. The focus is not on basic discovery science for its own sake, but on generating practical, decision-driving evidence that moves a candidate countermeasure closer to real-world use. The FOA sits within the NIH CounterACT program, which supports medical countermeasure research for chemical threats, and this R21 mechanism is positioned as an entry point that helps investigators produce the initial data needed to compete for larger, more advanced CounterACT or related translational awards later on.
The chemical threat scope is broad and includes multiple categories of agents that pose risks in warfare, terrorism, industrial accidents, and agricultural settings. Examples specifically cited include nerve agents such as sarin and VX; toxic industrial chemicals such as cyanide and phosgene; and toxic agricultural chemicals such as parathion and sodium fluoroacetate. The common thread is acute exposure leading to rapid, potentially lethal toxic effects where timely medical intervention can meaningfully change outcomes. Projects are expected to address therapeutics for treating these exposures, which can include new drugs, repurposed drugs, biologics, combinations, or other intervention strategies intended to mitigate acute toxicity and improve survival and functional recovery.
As an exploratory/developmental translational R21, the program emphasizes generation of preliminary preclinical evidence rather than full, late-stage development. Supported work is expected to produce tangible early datasets such as preclinical proof-of-concept, screening results, initial efficacy signals, dose or regimen exploration, and other foundational data that demonstrate feasibility and justify scaling to more extensive development. In practical terms, the FOA is aimed at bridging the gap between an interesting therapeutic idea and a more mature package of evidence that can support larger translational grants, including more robust efficacy studies, expanded pharmacology, advanced animal model work, or steps toward regulatory alignment.
From an administrative standpoint, this is a discretionary grant program offered by the National Institutes of Health, with activity spanning multiple NIH program areas as reflected by the CFDA listings (including environmental health and several biomedical and neuroscience-oriented extramural research programs). The award ceiling is listed as $250,000, and there is no cost sharing or matching requirement, which means applicants are not required to provide non-federal matching funds as a condition of the award.
Eligibility is intentionally broad across the U.S. research ecosystem. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations (including small businesses and other than small businesses), and a range of government entities such as state, county, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. Federally recognized tribal governments and other tribal organizations are included, along with regional organizations and U.S. territories or possessions. The FOA also explicitly notes eligibility for various institution types such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions, as well as faith-based or community-based organizations and eligible federal agencies.
At the same time, there are clear geographic restrictions: non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply directly. However, foreign components, as NIH defines them in its Grants Policy Statement, are allowed, meaning a U.S.-based applicant can include certain international elements when scientifically justified and compliant with NIH policy.
Key timeline details in the source record show the FOA was posted and created on October 3, 2012, with an original and current closing date of January 30, 2015, and an archive date of March 2, 2015. While those dates indicate this specific announcement is no longer active, the summary still reflects how the NIH CounterACT program structured exploratory translational funding at the time and what it prioritized: early, credible, preclinical translational evidence for therapeutics that can meaningfully reduce morbidity and mortality after acute chemical exposures. The full announcement was hosted through the NIH grants guide under the provided link (http://grants.nih.gov/grants/guide/pa-files/PAR-13-005.html), and NIH’s Office of Extramural Research webmaster contacts were listed for access or technical linking issues.
FAQs: Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21) - PAR-13-005
What is this funding opportunity?
This is an NIH grant opportunity under the Countermeasures Against Chemical Threats (CounterACT) program using the R21 Exploratory/Developmental mechanism. It is designed to kick-start early-stage translational research focused on developing or improving medical therapeutics that can reduce death and serious illness after acute exposure to high-priority chemical threat agents.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PAR-13-005.
What is the main goal of the program?
The goal is to generate practical, decision-driving evidence that moves a candidate medical countermeasure closer to real-world use for treating acute chemical exposures. The emphasis is on translational progress rather than basic discovery science for its own sake.
Is this opportunity focused on basic research or translational research?
It is focused on translational research. Projects are expected to produce early, actionable preclinical datasets that demonstrate feasibility and justify further development, rather than purely basic discovery findings.
What kinds of chemical threats are within scope?
The scope is broad and includes multiple categories of high-priority chemical threat agents that may arise from warfare, terrorism, industrial accidents, or agricultural settings. Examples cited include:
- Nerve agents (e.g., sarin, VX)
- Toxic industrial chemicals (e.g., cyanide, phosgene)
- Toxic agricultural chemicals (e.g., parathion, sodium fluoroacetate)
What types of exposures are targeted?
The opportunity targets acute exposures that lead to rapid, potentially lethal toxic effects where timely medical intervention can meaningfully change outcomes, including survival and functional recovery.
What kinds of countermeasures or therapeutics can be proposed?
Projects should address therapeutics intended to treat acute chemical exposures. The description explicitly includes possibilities such as new drugs, repurposed drugs, biologics, combinations, or other intervention strategies intended to mitigate acute toxicity and improve outcomes.
What stage of development is appropriate for an R21 under this FOA?
This R21 is positioned for exploratory/developmental translational work, emphasizing preliminary preclinical evidence rather than full late-stage development. It is meant to bridge the gap between an initial therapeutic idea and a stronger evidence package suitable for larger translational awards.
What kinds of results or deliverables is NIH expecting from funded projects?
Supported work is expected to produce tangible early datasets, such as preclinical proof-of-concept, screening results, initial efficacy signals, dose or regimen exploration, and other foundational data that demonstrate feasibility and support next-step development decisions.
What is meant by "decision-driving evidence" in this context?
In the context provided, it refers to practical data that helps determine whether a candidate therapeutic is viable and ready to be scaled into more extensive development, such as more robust efficacy work, expanded pharmacology, advanced animal model studies, or steps toward regulatory alignment.
How does this R21 fit into the broader CounterACT program?
It is described as an entry point within the NIH CounterACT program that helps investigators generate the initial data needed to compete for larger, more advanced CounterACT or related translational awards later on.
Which federal agency is offering this opportunity?
The opportunity is offered by the National Institutes of Health (NIH) as part of its CounterACT program.
What is the award ceiling?
The award ceiling listed is $250,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of the award.
Who is eligible to apply?
Eligibility is intentionally broad and includes a wide range of U.S. organizations and government entities. Examples listed include:
- Public and private institutions of higher education
- Nonprofit organizations (with or without 501(c)(3) status)
- For-profit organizations (including small businesses and other than small businesses)
- State, county, city or township governments
- Special district governments
- Independent school districts
- Public housing authorities/Indian housing authorities
- Federally recognized tribal governments and other tribal organizations
- Regional organizations
- U.S. territories or possessions
- Faith-based or community-based organizations
- Eligible federal agencies
Are specific institution types explicitly included (e.g., MSIs)?
Yes. The opportunity explicitly notes eligibility for institution types including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISI institutions.
Are non-U.S. (foreign) institutions eligible to apply directly?
No. The opportunity states that non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply directly.
Are any international elements allowed at all?
Yes. The opportunity notes that foreign components (as defined by NIH in its Grants Policy Statement) are allowed when included by a U.S.-based applicant, provided they are scientifically justified and compliant with NIH policy.
When was this FOA posted, and what are the key dates?
The source record indicates the FOA was posted/created on October 3, 2012. The original and current closing date listed is January 30, 2015. The archive date is March 2, 2015.
Is this funding opportunity still active?
Based on the dates provided (closing date January 30, 2015 and archive date March 2, 2015), this specific announcement is no longer active.
Where was the full announcement hosted?
The full announcement was hosted in the NIH grants guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-005.html
Who was listed for technical or access issues related to the announcement?
NIH's Office of Extramural Research webmaster contacts were listed for access or technical linking issues.
What does the opportunity say about the NIH program areas involved?
The description indicates it is a discretionary grant program offered by NIH, with activity spanning multiple NIH program areas as reflected by CFDA listings, including environmental health and several biomedical and neuroscience-oriented extramural research programs.
What is the practical value of this FOA if it is archived?
Even though the announcement is no longer active, the summary describes how the NIH CounterACT program structured exploratory translational funding at the time and what it prioritized: early, credible, preclinical translational evidence for therapeutics that can reduce morbidity and mortality after acute chemical exposures.
Browse more opportunities from the same category: Environment Health Income Security and Social Services
Next opportunity: Control Systems
Previous opportunity: Restorative Transplantation Research (RTR) Cooperative Agreement
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 005
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 005) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research on Autism Spectrum Disorders (R01) Apply for PA 13 216 Funding Number: PA 13 216 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Research on Autism Spectrum Disorders (R21) Apply for PA 13 217 Funding Number: PA 13 217 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Research on Autism Spectrum Disorders (R03) Apply for PA 13 218 Funding Number: PA 13 218 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Developmental Pharmacology and Toxicology Role of Ontogeny (R21) Apply for PAR 13 308 Funding Number: PAR 13 308 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Developmental Pharmacology and Toxicology Role of Ontogeny (R03) Apply for PAR 13 307 Funding Number: PAR 13 307 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Developmental Pharmacology and Toxicology Role of Ontogeny (R01) Apply for PAR 13 306 Funding Number: PAR 13 306 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Environmental Contributors to Autism Spectrum Disorders (R01) Apply for PAR 14 203 Funding Number: PAR 14 203 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $400,000 |
| Environmental Contributors to Autism Spectrum Disorders (R21) Apply for PAR 14 202 Funding Number: PAR 14 202 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Centers of Excellence on Environmental Health Disparities Research (P50) Apply for RFA ES 14 010 Funding Number: RFA ES 14 010 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,000,000 |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 15 146 Funding Number: PAR 15 146 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21) Apply for PAR 15 315 Funding Number: PAR 15 315 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic Susceptibility and Variability of Human Structural Birth Defects (R01) Apply for PA 08 011 Funding Number: PA 08 011 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R03) Apply for PAR 08 215 Funding Number: PAR 08 215 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R21) Apply for PAR 08 216 Funding Number: PAR 08 216 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Genetic and Genomic Analysis of Xenopus (R01) Apply for PAR 09 240 Funding Number: PAR 09 240 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic and Genomic Analysis of Xenopus (R21) Apply for PAR 09 241 Funding Number: PAR 09 241 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 10 180 Funding Number: PAR 10 180 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 10 181 Funding Number: PAR 10 181 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R01) Apply for PAR 11 057 Funding Number: PAR 11 057 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $499,999 |
| Developmental Pharmacology (R03) Apply for PAR 11 058 Funding Number: PAR 11 058 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 005", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.